Literature DB >> 20190792

Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan.

Chiyo K Imamura, Naoko Takebe, Seigo Nakamura, Hideyuki Saya, Naoto T Ueno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20190792     DOI： 10.1038/nrclinonc.2010.13

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  3 in total

1.  Follow the leader.

Authors:  Kaori Tsuji; Kiichiro Tsutani
Journal:  Nature       Date:  2008-06-12       Impact factor: 49.962

Review 2.  Improving cancer outcomes through international collaboration in academic cancer treatment trials.

Authors:  Edward L Trimble; Jeffrey S Abrams; Ralph M Meyer; Fabien Calvo; Eduardo Cazap; James Deye; Elizabeth Eisenhauer; Thomas J Fitzgerald; Denis Lacombe; Max Parmar; Nita Seibel; Lalitha Shankar; Ann Marie Swart; Patrick Therasse; Bhadrasain Vikram; Remy von Frenckell; Michael Friedlander; Keiichi Fujiwara; Richard S Kaplan; Francoise Meunier
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

3.  Reimbursement for cancer treatment: coverage of off-label drug indications.

Authors: 
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544
  3 in total
  2 in total

1.  International models of investigator-initiated trials: implications for Japan.

Authors:  E L Trimble; J Ledermann; K Law; T Miyata; C K Imamura; B-H Nam; Y H Kim; Y-J Bang; M Michaels; D Ardron; S Amano; Y Ando; T Tominaga; K Kurokawa; N Takebe
Journal:  Ann Oncol       Date:  2012-07-25       Impact factor: 32.976

2.  Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan.

Authors:  Shunsuke Kondo; Hiroko Hosoi; Kota Itahashi; Jun Hashimoto
Journal:  Cancer Sci       Date:  2017-05-16       Impact factor: 6.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.